Allogene Therapeutics Initiates Phase 2 Trial Investigating Cemacabtagene Ansegedleucel As Part Of First Line Treatment For Patients With Large B-Cell Lymphoma Likely to Relapse
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics has initiated a Phase 2 trial (ALPHA3) to investigate Cemacabtagene Ansegedleucel (Cema-cel) as part of the first-line treatment for patients with large B-cell lymphoma (LBCL) likely to relapse. The trial aims to improve cure rates and incorporates Foresight Diagnostics's CLARITY™ test to identify patients with minimal residual disease (MRD). The trial is expected to complete enrollment in the first half of 2026, with a BLA submission anticipated in 2027.
June 20, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Allogene Therapeutics has started a Phase 2 trial for Cemacabtagene Ansegedleucel (Cema-cel) as a first-line treatment for LBCL patients likely to relapse. The trial includes the CLARITY™ test to identify patients with minimal residual disease. Enrollment is expected to complete in 1H 2026, with a BLA submission in 2027.
The initiation of the Phase 2 trial for Cema-cel as a first-line treatment for LBCL patients likely to relapse is a significant development for Allogene Therapeutics. The inclusion of the CLARITY™ test to identify patients with minimal residual disease could improve the trial's success rate. The expected completion of enrollment by the first half of 2026 and the anticipated BLA submission in 2027 indicate a clear timeline for potential market entry, which is likely to positively impact the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100